Share this post on:

Difficult To Treat, Impossible to Cure

Neurodegenerative diseases—such as Alzheimer’s, Parkinson’s, ALS, and Huntington’s disease—are among the most formidable challenges in modern medicine. Their complexity stems from a combination of biological hurdles, the unique environment of the central nervous system, and the subtle ways these conditions develop and progress.

The medical term for prion disease is transmissible spongiform encephalopathy (TSE). As the name implies, TSEs are transmissible, which puts caregivers, family members, friends and entire health care systems at risk. The pathogen is a deadly form of protein known as a prion. Prions are impossible to stop in the body and they are impossible to stop in homes, hospitals and beyond.

Once a person becomes infected, their bodily fluids and cell tissue become infectious. Blood, saliva, mucus, skin, urine, feces and more are infected long before the person exhibits any symptoms. People who have TSE should be quarantined, but many are still working, travelling, shopping and eating out at restaurants until symptoms become an obstacle. When it comes to TSE and the global prion pandemic, answers begin with the truth. 

Why Diagnosis is Difficult

Insidious Onset and Subtle Early Symptoms. Neurodegeneration begins years, sometimes decades, before symptoms appear. Early signs—like mild forgetfulness, slight tremors, or fatigue—are easily mistaken for normal aging, stress, or other health issues, delaying the initial visit to a physician.

Overlap in Clinical Presentations. Many neurodegenerative disorders share overlapping symptoms. For example, several conditions cause cognitive decline or movement issues, making it difficult to pinpoint the exact underlying pathology based on clinical observation alone.

Inaccessible Target Organ. Unlike other medical fields where a tissue biopsy is routine (such as in oncology or dermatology), the brain and spinal cord are enclosed within bone and delicate membranes. Accessing living neural tissue for direct examination is invasive and high-risk.

Limitations of Traditional Biomarkers. Historically, definitive diagnosis often required a post-mortem autopsy to look for hallmark protein aggregates (like amyloid plaques, tau tangles, or Lewy bodies). While diagnostic imaging (PET scans, MRIs) and cerebrospinal fluid (CSF) testing have advanced significantly, finding universally accessible, highly specific, and early blood-based biomarkers remains an active area of research.

Alzheimer's disease transmissible via skin and bodily fluids

Why Treatment is Difficult

The Blood-Brain Barrier (BBB). The brain is heavily protected by a specialized layer of endothelial cells that tightly regulate what enters the central nervous system. While this barrier protects the brain from toxins and pathogens, it also blocks more than 98 percent of systemic pharmaceutical drugs from reaching therapeutic concentrations in brain tissue.

Selective Neuronal Vulnerability and Irreversibility. Neurons are post-mitotic cells, meaning most do not divide or easily regenerate once mature. When neurodegenerative diseases cause cell death, the loss is generally permanent. Current therapies often aim to slow progression or manage symptoms, but they cannot easily replace lost neural circuitry.

Complex, Multi-Faceted Pathology. These diseases rarely have a single, isolated cause. They involve intricate cascades of protein misfolding, mitochondrial dysfunction, oxidative stress, neuroinflammation, and genetic risk factors. Targeting just one pathway or protein often proves insufficient because the disease networks are robust and redundant.

Late Intervention. By the time a patient is formally diagnosed and treatment begins, a significant portion of vulnerable neurons may already be irreversibly damaged. Intervening at the symptomatic stage is often analogous to treating a house fire after it has already consumed the foundation.

Overcoming the blood-brain barrier is one of the fastest-evolving frontiers in neuroscience. Recent breakthroughs shift the paradigm from simply “forcing” drugs through the barrier to hijacking natural transport systems, utilizing precision physical forces, or deploying smart nanocarriers.

Research and Development

Molecular “Trojan Horse.” Instead of trying to squeeze large molecules like antibodies or gene therapies through the BBB, scientists are designing antibodies that act as molecular Trojan horses (receptor-mediated transcytosis).

  • How it works: One arm of the antibody binds to a disease target (like amyloid-beta or alpha-synuclein), while the other arm attaches to a natural receptor on the surface of the BBB endothelial cells (such as the transferrin receptor or the iron-shuttling receptor).
  • Recent Progress: Technologies like Roche’s “Brainshuttle” platform (used in candidates like trontinemab for Alzheimer’s) actively hitch a ride on these natural transport pathways. Clinical trials show that this active transport can clear brain plaques significantly faster and at much lower doses than conventional passive-penetration antibodies.

Focused Ultrasound + Microbubbles. For gene therapies, stem cells, or high-dose biologics that cannot easily be chemically modified, non-invasive physical disruption is gaining massive traction.

  • How it works: Patients are injected with microscopic gas-core bubbles. Doctors then apply low-intensity pulsed focused ultrasound waves to targeted regions of the brain. When the ultrasound waves hit the microbubbles, they oscillate safely and transiently loosen the tight junctions of the BBB for a few hours.
  • Recent Progress: Clinical trials targeting mild Alzheimer’s and Parkinson’s patients have demonstrated high technical success and safety. Notably, combining focused ultrasound with anti-amyloid treatments has been shown in studies to significantly enhance local plaque clearance in the sonicated regions by allowing therapeutics to flood directly into the affected tissue.

Advanced Nanocarriers and Biomimetic Nanoparticles. Nanotechnology has evolved beyond simple encapsulation to create smart nanoparticles capable of navigating the neurovascular unit.

  • How it works: Researchers engineer polymeric, lipid-based, or protein-based nanoparticles coated with specific ligands (such as peptides or glucose derivatives) that trigger adsorptive-mediated transport across the BBB. Once inside the brain parenchyma, these particles can be programmed to release their payload (such as anti-inflammatory agents or gene-editing tools) directly into specific cell types like neurons or microglia.
  • Recent Progress: Preclinical studies have shown success in using specialized nanocarriers to cross the BBB and target pathways involved in Parkinson’s and Alzheimer’s, simultaneously clearing toxic protein aggregates and dampening neuroinflammation.

Convection-Enhanced Delivery. When localized, high-concentration delivery is required deep within brain structures (such as the putamen in Parkinson’s disease), direct physical delivery bypasses the circulatory system altogether.

  • How it works: Neurosurgeons use thin, reflux-resistant micro-cannulae threaded directly into targeted brain parenchyma, utilizing a pressure-driven gradient to continuously and evenly infuse therapeutics (like viral vectors for gene therapy) across wide tissue areas.
  • Recent Progress: Advanced real-time MRI-guided tracking allows physicians to monitor the spread of the infusate live during surgery, ensuring the treatment reaches deep-brain nuclei accurately without damaging surrounding tissue.

Antibodies are playing an increasingly central role in the search for effective treatments against prion diseases—fatal, neurodegenerative conditions caused by misfolded prion proteins that trigger a domino effect of structural deformation in normal brain proteins.

Unlike traditional small-molecule drugs that struggle to target protein-protein interactions, therapeutic monoclonal antibodies (mAbs) can be engineered to bind with high specificity to target proteins. However, applying them to prion diseases involves unique and formidable scientific hurdles.

Antibodies Target Prions. Monoclonal antibodies can bind to the normal cellular prion protein (PrPC) or the pathological form (PrPSc), effectively masking binding sites. This prevents the abnormal protein from interacting with normal proteins and halting the chain reaction of misfolding. Binding of antibodies to prion aggregates signals microglia and other immune cells in the central nervous system to engulf and degrade the toxic clumps via phagocytosis. Certain antibodies bind to specific domains of the prion protein, stabilizing its normal structure and preventing it from unfolding into the toxic conformation.

prion disease is an infectious disease

The Future Of Neurodegenerative Disease

Prion disease is now the fastest-growing cause of death in the world. Unfortunately, there are still more questions than answers with neurodegenerative disease. Most importantly, we know that prevention is our only hope. We know that most forms of neurodegenerative disease are forms of prion disease. The biggest difference between Alzheimer’s disease and Parkinson’s disease, for example, is the region of the brain that is under the initial prion attack. The only difference between mad cow disease and Alzheimer’s disease is the species that is under attack. Prion disease is prion disease, but no two cases are identical. One of these reasons for the variation in symptoms is the fact that prions migrate, mutate and multiply. There are now millions of mutations infecting mammals around the world.

Share this post on:
Avatar Gary Chandler

Author: Gary Chandler

Gary Chandler is a prion expert. Chandler is connecting the dots to the global surge in neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, Creutzfeldt-Jakob disease, chronic wasting disease and other forms of prion disease.